Steven Lichtman
Stock Analyst at Oppenheimer
(3.05)
# 1,378
Out of 5,072 analysts
71
Total ratings
41.18%
Success rate
13.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $21.03 | +4.64% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $327.19 | +11.56% | 7 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $101.58 | +23.06% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $63.47 | +60.71% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $97.52 | +38.43% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.35 | +124.30% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $79.31 | +38.70% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $105.33 | -10.76% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $11.42 | +469.18% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $17.49 | -37.11% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $12.40 | -3.23% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $86.60 | +0.46% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.40 | +773.04% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $371.18 | -22.41% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $106.29 | -1.21% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $26.52 | +465.61% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $77.93 | +9.07% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $21.03
Upside: +4.64%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $327.19
Upside: +11.56%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $101.58
Upside: +23.06%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $63.47
Upside: +60.71%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $97.52
Upside: +38.43%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.35
Upside: +124.30%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $79.31
Upside: +38.70%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $105.33
Upside: -10.76%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $11.42
Upside: +469.18%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $17.49
Upside: -37.11%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $12.40
Upside: -3.23%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $86.60
Upside: +0.46%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.40
Upside: +773.04%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $371.18
Upside: -22.41%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $106.29
Upside: -1.21%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $26.52
Upside: +465.61%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $77.93
Upside: +9.07%